Abstract:Background: Endogenous insulin supplementation is essential for individuals with type 1 diabetes (T1D). However, current treatments, including pancreas transplantation, insulin injections, and oral medications, have significant limitations. The development of engineered cells that can secrete endogenous insulin offers a promising new therapeutic strategy for type 1 diabetes (T1D). This approach could potentially circumvent autoimmune responses associated with the transplantation of differentiated β-cells or systemic delivery of viral vectors. Methods: We utilized CRISPR/Cas9 gene editing coupled with homology-directed repair (HDR) to precisely integrate a promoter-free EMCVIRES-insulin cassette into the 3' untranslated region (UTR) of the GAPDH gene in human HEK-293T cells. Subsequently quantified insulin expression levels in these engineered cells, the viability and functionality of the engineered cells when seeded on different cell vectors (GelMA and Cytopore I) were also assessed. Finally, we investigated the therapeutic potential of EMCVIRES-based insulin secretion circuits in reversing Hyperglycaemia in T1D mice. Result: Our results demonstrate that HDR-mediated gene editing successfully integrated the IRES-insulin loop into the genome of HEK-293T cells, a non-endocrine cell line, enabling the expression of human-derived insulin. Furthermore, Cytopore I microcarriers facilitated cell attachment and proliferation during in vitro culture and enhanced cell survival post-transplantation. Transplantation of these cell-laden microcarriers into mice led to the development of a stable, fat-encapsulated structure. This structure exhibited the expression of the platelet-endothelial cell adhesion molecule CD31, and no significant immune rejection was observed throughout the experiment. Diabetic mice that received the cell carriers reversed hyperglycemia, and blood glucose fluctuations under simulated feeding stimuli were very similar to those of healthy mice. Conclusion: In summary, our study demonstrates that Cytopore I microcarriers are biocompatible and promote long-term cell survival in vivo. The promoter-free EMCVIRES-insulin loop enables non-endocrine cells to secrete mature insulin, leading to a rapid reduction in glucose levels. We have presented a novel promoter-free genetic engineering strategy for insulin secretion and proposed an efficient cell transplantation method. Our findings suggest the potential to expand the range of cell sources available for the treatment of diabetes, offering new avenues for therapeutic interventions.

Function of Isolated Pancreatic Islets From Patients at Onset of Type 1 Diabetes: Insulin Secretion Can Be Restored After Some Days in a Nondiabetogenic Environment In Vitro

In Vitro Expansion of Pancreatic Islet Clusters Facilitated by Hormones and Chemicals.

187-OR: Declines in ß-Cell Glucose Responsiveness Correlate with Loss of Glucose Metabolism during T1D Pathogenesis

Development of Type 1 Diabetes may occur through a Type 2 Diabetes mechanism

Expression of Interferon-Stimulated Genes in Insulitic Pancreatic Islets of Patients Recently Diagnosed With Type 1 Diabetes

In Vivo And In Vitro Characterization Of Insulin-Producing Cells Obtained From Murine Bone Marrow

Single-cell multi-omics analysis of human pancreatic islets reveals novel cellular states in type 1 diabetes

Enterovirus infection of human islets of Langerhans affects β-cell function resulting in disintegrated islets, decreased glucose stimulated insulin secretion and loss of Golgi structure

Pancreatic Islet Cell Therapy for Type I Diabetes: Understanding the Effects of Glucose Stimulation on Islets in Order to Produce Better Islets for Transplantation

Pancreatic islets seeded in a novel bioscaffold forms an organoid to rescue insulin production and reverse hyperglycemia in models of type 1 diabetes

Stem cells reverse type 1 diabetes

The future treatment for type 1 diabetes: Pig islet- or stem cell-derived β cells?

Insulin-Producing Cells from Human Pancreatic Islet-Derived Progenitor Cells Following Transplantation in Mice

A Novel Islet Isolation Method from Living Donors

Expression of immunoreactive inducible nitric oxide synthase in pancreatic islet cells from newly diagnosed and long-term type 1 diabetic donors is heterogeneous and not disease-associated

Insulin gene transfer enhances the function of human islet grafts

Structural And Functional Abnormalities In The Islets Isolated From Type 2 Diabetic Subjects

Engineered IRES-mediated promoter-free insulin-producing cells reverse hyperglycemia

In vitro derivation of functional insulin-producing cells from human embryonic stem cells

Impaired islet function with normal exocrine enzyme secretion is consistent across the head, body, and tail pancreas regions in type 1 diabetes

Impaired islet function and normal exocrine enzyme secretion occur with low inter-regional variation in type 1 diabetes